Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease

2003/04/01 by F. X. Kleber, Franz-Xaver Kleber, Christian Witt +7 · 31 citations
Medicine · #Atrial Fibrillation Management and Outcomes #Cardiology #Heart failure #Heparin #Heparin-Induced Thrombocytopenia and Thrombosis #Intensive care medicine #Internal medicine #Lung #Medicine #Randomized controlled trial #Respiratory disease #Surgery #Thrombosis #Venous Thromboembolism Diagnosis and Management #Venous thromboembolism

paper · doi:10.1067/mhj.2003.189

openalex publication_date 2003/04/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/25

Cited by

• Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients
• Prevention of Venous Thromboembolism
• 2013 ACCF/AHA Guideline for the Management of Heart Failure
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
• Prevention of VTE in Nonsurgical Patients
• American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients
• Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. [europepmc]
• An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients. [europepmc]
• Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. [europepmc]
• Incidence and cost burden of post-thrombotic syndrome. [europepmc]
• Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts. [europepmc]
• Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. [europepmc]
• Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims. [europepmc]
• Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. [europepmc]
• Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. [europepmc]
• Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). [europepmc]
• Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study. [europepmc]
• Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. [europepmc]
• American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. [europepmc]
• What has changed in venous thromboembolism prophylaxis for hospitalized patients over recent decades: review article. [europepmc]
• Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients. [europepmc]
• Role of ambulation to prevent venous thromboembolism in medical patients: where do we stand? [europepmc]
• Deep Vein Thrombosis in the Uninjured Limb in Patients with Lower Extremity Fractures: A Retrospective Study. [europepmc]
• Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study. [europepmc]
• Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. [europepmc]
• Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients. [europepmc]
• Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. [europepmc]
• Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study. [europepmc]
• Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients. [europepmc]
• Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity. [europepmc]
• Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study. [europepmc]